Literature DB >> 16946712

A Web-based data warehouse on gene expression in human malignant melanoma.

Balazs Györffy1, Hermann Lage.   

Abstract

The identification of melanoma-specific dysregulated genes could identify new molecular markers. By applying bioinformatic tools for screening of biomedical databases, a melanoma-specific gene expression profile "data warehouse" was constructed. Utilizable data sets of global gene expression analyses were available from nine studies that applied different technology platforms. A single study used cell lines, five investigations analyzed cell lines and tissues obtained from patients, two studies used exclusively specimens obtained from patients, and one study analyzed blood cells prepared from patients. The total number of investigated patients was 116. From 815 differential-regulated genes, 772 (95%) were identified merely in a single study, 37 in at least two studies, five (RAB33A, ERBB3, ADRB2, MERTK, SNF1LK, and ITPKB) in at least three studies, and a single gene, RAB33A, in four studies. These data show that the accuracy, reproducibility, and comparability among different gene expression profile studies are low in melanoma. In conclusion, the study demonstrates the high diversity of gene expression profiles associated with melanoma, the necessity to include a sufficient number of samples regarding clinical standards, for the design of standardized sample collecting and preparation, for the development of common standards for microarray data processing, and for developing standardized bioinformatic tools.

Entities:  

Mesh:

Year:  2006        PMID: 16946712     DOI: 10.1038/sj.jid.5700543

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  15 in total

Review 1.  Macrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands.

Authors:  Thomas Schmidt; Isabel Ben-Batalla; Alexander Schultze; Sonja Loges
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

2.  Human inositol 1,4,5-trisphosphate 3-kinase isoform B (IP3KB) is a nucleocytoplasmic shuttling protein specifically enriched at cortical actin filaments and at invaginations of the nuclear envelope.

Authors:  Marcus M Nalaskowski; Ralf Fliegert; Olga Ernst; Maria A Brehm; Werner Fanick; Sabine Windhorst; Hongying Lin; Susanne Giehler; Jamin Hein; Yuan-Na Lin; Georg W Mayr
Journal:  J Biol Chem       Date:  2010-12-09       Impact factor: 5.157

Review 3.  Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors.

Authors:  Rachel M A Linger; Amy K Keating; H Shelton Earp; Douglas K Graham
Journal:  Expert Opin Ther Targets       Date:  2010-10       Impact factor: 6.902

4.  Phosphoproteomic screen identifies potential therapeutic targets in melanoma.

Authors:  Kathryn Tworkoski; Garima Singhal; Sebastian Szpakowski; Christina Ivins Zito; Antonella Bacchiocchi; Viswanathan Muthusamy; Marcus Bosenberg; Michael Krauthammer; Ruth Halaban; David F Stern
Journal:  Mol Cancer Res       Date:  2011-04-26       Impact factor: 5.852

5.  MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL.

Authors:  Kathryn A Tworkoski; James T Platt; Antonella Bacchiocchi; Marcus Bosenberg; Titus J Boggon; David F Stern
Journal:  Pigment Cell Melanoma Res       Date:  2013-05-21       Impact factor: 4.693

Review 6.  TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer.

Authors:  Rachel M A Linger; Amy K Keating; H Shelton Earp; Douglas K Graham
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

Review 7.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

8.  Clinical use of an enterprise data warehouse.

Authors:  R Scott Evans; James F Lloyd; Lee A Pierce
Journal:  AMIA Annu Symp Proc       Date:  2012-11-03

Review 9.  The promise of anti-ErbB3 monoclonals as new cancer therapeutics.

Authors:  Luigi Aurisicchio; Emanuele Marra; Giuseppe Roscilli; Rita Mancini; Gennaro Ciliberto
Journal:  Oncotarget       Date:  2012-08

10.  Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression.

Authors:  Byungwoo Ryu; Dave S Kim; Amena M Deluca; Rhoda M Alani
Journal:  PLoS One       Date:  2007-07-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.